VAXNEUVANCE
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $80,601 | 561 | 478 |
| 2023 | $244,172 | 1,331 | 1,024 |
| 2022 | $63,812 | 634 | 563 |
| 2021 | $229.52 | 13 | 13 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $218,045 | 99 | 56.1% |
| Food and Beverage | $95,501 | 2,158 | 24.6% |
| Travel and Lodging | $61,095 | 218 | 15.7% |
| Unspecified | $13,114 | 2 | 3.4% |
| Education | $1,059 | 62 | 0.3% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| STUDY NAME#Response to guideline-concordant pneumococcal vaccination strategy in cardiac transplant candidates and recipients | Merck Sharp & Dohme LLC | $6,654 | 0 |
| Response to guideline-concordant pneumococcal vaccination strategy in cardiac transplant candidates and recipients | Merck Sharp & Dohme LLC | $6,460 | 0 |
Top Doctors Receiving Payments for VAXNEUVANCE — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Student in an Organized Health Care Education/Training Program | Yabucoa, PR | $208.50 | 3 |
| , M.D | Specialist | Humacao, PR | $208.50 | 3 |
| , M.D | Pediatrics | Carolina, PR | $204.19 | 5 |
| , M.D | Pediatrics | Harvey, IL | $190.44 | 2 |
| , M.D | Pediatrics | Carolina, PR | $175.20 | 3 |
| , M.D | Internal Medicine | San Juan, PR | $168.98 | 2 |
| , MD | Pediatrics | Caguas, PR | $168.47 | 2 |
| , M.D | Pediatrics | San Juan, PR | $154.71 | 3 |
| , M.D | Pediatrics | Far Rockaway, NY | $150.67 | 2 |
| , MD | Infectious Disease | Kingston, NY | $144.38 | 1 |
| , M.D | Infectious Disease | Novi, MI | $144.38 | 1 |
| , MD | Pediatrics | Detroit, MI | $144.38 | 1 |
| , M.D | Pediatric Infectious Diseases | Detroit, MI | $144.38 | 1 |
| , MD | Pediatric Infectious Diseases | Albany, NY | $144.38 | 1 |
| , MD | Emergency Medicine | Chatham, NJ | $144.38 | 1 |
| , MD | Infectious Disease | Miami, FL | $144.38 | 1 |
| , MD | Pediatric Hematology-Oncology | Nashville, TN | $144.38 | 1 |
| , M.D., | Infectious Disease | Gainesville, GA | $144.38 | 1 |
| , M.D | Internal Medicine | Sun City West, AZ | $144.38 | 1 |
| Erica Herc | Infectious Disease | Detroit, MI | $144.38 | 1 |
| , MD | Pediatric Infectious Diseases | Jacksonville, FL | $144.38 | 1 |
| , M.D | Internal Medicine | New York, NY | $144.38 | 1 |
| , MD | Pediatrics | Irvine, CA | $143.83 | 2 |
| , M.D | Hospitalist | Mayaguez, PR | $143.62 | 3 |
| , MD | Pediatrics | Ponce, PR | $143.62 | 3 |
Manufacturing Companies
- Merck Sharp & Dohme LLC $388,584
- Merck Sharp & Dohme Corporation $229.52
Product Information
- Type Biological
- Total Payments $388,814
- Total Doctors 1,929
- Transactions 2,539
About VAXNEUVANCE
VAXNEUVANCE is a biological associated with $388,814 in payments to 1,929 healthcare providers, recorded across 2,539 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2021 to 2024. In 2024, $80,601 was paid across 561 transactions to 478 doctors.
The most common payment nature for VAXNEUVANCE is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($218,045, 56.1% of total).
VAXNEUVANCE is associated with 2 research studies, including "STUDY NAME#Response to guideline-concordant pneumococcal vaccination strategy in cardiac transplant candidates and recipients" ($6,654).